No­vo Nordisk nabs pri­or­i­ty re­view vouch­er for $110M from Mar­i­nus as the biotech preps first drug launch

When Mar­i­nus Phar­ma­ceu­ti­cals com­plet­ed its turn­around and fi­nal­ly pushed its sole drug across the FDA fin­ish line, the com­pa­ny not­ed it would sell the pri­or­i­ty re­view vouch­er it re­ceived for its ef­forts. On Thurs­day, Mar­i­nus re­vealed the buy­er — and it’s a big name.

Dan­ish phar­ma No­vo Nordisk bought the vouch­er for $110 mil­lion, Mar­i­nus said in an SEC fil­ing ear­ly Thurs­day, giv­ing one of its pro­grams a free pass to an ac­cel­er­at­ed re­view process. It’s the third vouch­er No­vo has bought since 2014, ac­cord­ing to the End­points News tal­ly, tied for fourth-most among bio­phar­ma com­pa­nies in that span.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER